Century Therapeutics keeps CNTY-813 IND filing on track for Q4 2026

Oct 2, 2026 12:05 (22d ago)

Verifying

Century Therapeutics presented updated nonclinical CNTY-813 data at the EASD annual meeting.
Five clinical-scale batches met consistent final product profiles through the 29-day manufacturing process.
Century expects to submit the CNTY-813 IND application in Q4 2026.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.